Terapija zasnovana na virtuelnoj stvarnosti poboljšava umor, uticaj i kvalitet života kod pacijenata sa multiplom sklerozom. Sistematski pregled sa meta-analizom.
Sensors (Basel, Switzerland)
Sažetak istraživanja
Patients with multiple sclerosis (PwMS) have a high level of fatigue and a reduced quality of life (QoL) due to the impact of multiple sclerosis (MS). Terapija zasnovana na virtuelnoj stvarnosti (VRBT) se koristi za smanjenje invaliditeta kod PwMS-a.
Cilj ove studije je bio da se proceni efekat VRBT na umor, uticaj MS i QoL u PwMS.
Methods A systematic review with meta-analysis was conducted through a bibliographic search on PubMed, Scopus, Web of Science, and PEDro up to April 2021. We included randomized controlled trials (RCTs) with PwMS that received VRBT in comparison to conventional therapy (CT) including physiotherapy, balance and strength exercises, and stretching or physical activity, among others; ili u poređenju sa jednostavnim posmatranjem; kako bi se procijenio umor, MS-uticaj i QoL. Veličina efekta je izračunata korištenjem Cohenove standardizirane srednje razlike sa 95% intervalom povjerenja (95% CI).
Rezultati Uključeno je 12 RCT studija koje su dale podatke od 606 PwMS (42,83 ± 6,86 godina i 70% žena). Metodološki prosjek kvaliteta, prema skali PEDro, iznosio je 5,83 ± 0,83 boda. Our global findings showed that VRBT is effective at reducing fatigue (SMD -0.33; 95% CI -0.61, -0.06), lowering the impact of MS (SMD -0.3; 95% CI -0.55, -0.04), and increasing overall QoL (0.5; 95% CI 0.23, 0.76). Subgroup analysis showed the following: (1) VRBT is better than CT at reducing fatigue (SMD -0.4; 95% CI -0.7, -0.11), as well as in improving the mental dimension of QoL (SMD 0.51; 95% CI 0.02, 1); (2) VRBT is better than simple observation at reducing the impact of MS (SMD -0.61; 95% CI -0.97, -0.23) and increasing overall QoL (SMD 0.79; 95% CI 0.3, 1.28); and (3) when combined with CT, VRBT is more effective than CT in improving the global (SMD 0.6, 95% CI 0.13, 1.07), physical (SMD 0.87; 95% CI 0.3, 1.43), and mental dimensions (SMD 0.6; 95% CI 0.08, 1.11) of QoL.
Zaključak VRBT je efikasan u smanjenju umora i uticaja MS-a i poboljšanju kvaliteta života u PwMS-u.
Prikaži originalni naslov i sažetak na engleskom
Virtual Reality-Based Therapy Improves Fatigue, Impact, and Quality of Life in Patients with Multiple Sclerosis. A Systematic Review with a Meta-Analysis.
Patients with multiple sclerosis (PwMS) have a high level of fatigue and a reduced quality of life (QoL) due to the impact of multiple sclerosis (MS). Virtual reality-based therapy (VRBT) is being used to reduce disability in PwMS. The aim of this study was to assess the effect of VRBT on fatigue, the impact of MS, and QoL in PwMS.
Methods A systematic review with meta-analysis was conducted through a bibliographic search on PubMed, Scopus, Web of Science, and PEDro up to April 2021. We included randomized controlled trials (RCTs) with PwMS that received VRBT in comparison to conventional therapy (CT) including physiotherapy, balance and strength exercises, and stretching or physical activity, among others; or in comparison to simple observation; in order to assess fatigue, MS-impact, and QoL. The effect size was calculated using Cohen's standardized mean difference with a 95% confidence interval (95% CI).
Results Twelve RCTs that provided data from 606 PwMS (42.83 ± 6.86 years old and 70% women) were included. The methodological quality mean, according to the PEDro Scale, was 5.83 ± 0.83 points. Our global findings showed that VRBT is effective at reducing fatigue (SMD -0.33; 95% CI -0.61, -0.06), lowering the impact of MS (SMD -0.3; 95% CI -0.55, -0.04), and increasing overall QoL (0.5; 95% CI 0.23, 0.76). Subgroup analysis showed the following: (1) VRBT is better than CT at reducing fatigue (SMD -0.4; 95% CI -0.7, -0.11), as well as in improving the mental dimension of QoL (SMD 0.51; 95% CI 0.02, 1); (2) VRBT is better than simple observation at reducing the impact of MS (SMD -0.61; 95% CI -0.97, -0.23) and increasing overall QoL (SMD 0.79; 95% CI 0.3, 1.28); and (3) when combined with CT, VRBT is more effective than CT in improving the global (SMD 0.6, 95% CI 0.13, 1.07), physical (SMD 0.87; 95% CI 0.3, 1.43), and mental dimensions (SMD 0.6; 95% CI 0.08, 1.11) of QoL.
Conclusion VRBT is effective at reducing fatigue and MS impact and improving QoL in PwMS.
Izvorni podaci
- DOI
- 10.3390/s21217389
- PMID
- 34770694
- PMCID
- PMC8588272
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom